Improving the clarification, characterization, and homogeneity of animal serum through Nanotrap nanoparticle technology

通过 Nanotrap 纳米颗粒技术提高动物血清的澄清度、表征和均质性

• 批准号: 10274670
• 负责人: Benjamin Scott Lepene
• 金额: $ 16.24万
• 依托单位: CERES NANOSCIENCES, LLLP
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2021-05-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10274670
• 关键词: 2019-nCoV; Address; Agreement; Amendment; Animals; Antibodies; Antigens; Anus; Architecture; Biological; Biological Assay; Blood; Blood specimen; COVID-19; COVID-19 detection; COVID-19 outbreak; COVID-19 testing; Cattle; Clinical; Collection; Communication; Complex; Coronavirus; Coughing; Detection; Diagnostic; Diagnostic tests; Disease Outbreaks; Funding; Future; Gagging; Gold; Grant; Gravitation; Health Personnel; Home; Human; Immunoglobulin G; Immunoglobulin M; Individual; Legal patent; Methods; Molecular; Molecular Diagnostic Testing; National Institute of General Medical Sciences; Patient Education; Patients; Performance; Phase; Population; RNA; Rapid screening; Reporting; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 infection; Saliva; Sampling; Sensitivity and Specificity; Serum; Signal Transduction; Site; Small Business Innovation Research Grant; Sneezing; Specimen; Swab; Technology; Testing; Time; Urine; Virion; Virus; Whole Blood; Work; antibody test; betacoronavirus; biobank; clinical diagnostics; cost; detection limit; diagnostic assay; diagnostic technologies; falls; feasibility testing; home test; improved; nanoparticle; nanoscience; particle; patient population; rapid diagnosis; respiratory; response; saliva sample; salivary assay; screening; tool; underserved community; ventilation

PROJECT SUMMARY SARS-CoV-2 is the β-coronavirus causing the current coronavirus disease 2019 (COVID-19) outbreak. Large- scale diagnostic testing and large-scale screening are key tools used to contain outbreaks, and are especially important for something as transmissible as SARS-CoV-2. While various clinical specimens—like blood, pharyngeal swabs, saliva, anal swabs, and urine—have showed the presence of the virus in infected patients, there has been a recent gravitation towards the use of saliva samples due to their ease of collection, at-home collection potential, and adaptability. Despite these advantages, the detection of SARS-CoV-2 RNA, antigen, or virus in saliva samples is variable, ranging from 30% to 100% sensitivity, due to the fact that saliva is a complex biosolution. This high variability also means that there tends to be a high background signal for almost all molecular assays tested, which obfuscates accurate testing and rapid tracking capabilities. To address this need, Ceres Nanosciences proposes a competitive 1-year supplement onto its existing Phase I SBIR grant (1R43GM135943; 02/01/2020–10/31/2020; NIGMS) to test the feasibility of using its proprietary and patented Nanotrap® technology to significantly improve the detection of SARS-CoV-2 from saliva samples using existing molecular diagnostics assays on the market today. This supplemental aim falls within the scope of the ongoing funded project, which is evaluating the feasibility of using Nanotrap particles to improve the extraction of common contaminants—including viruses—from bovine serum. The supplemental work will apply a similar workflow to evaluate the feasibility of leveraging Nanotrap particles and workflow to cost- and time-effectively screen small and large volumes of saliva and biobanked whole blood and serum specimens for the presence of SARS-CoV- 2 virus or antibody.

项目摘要 SARS-COV-2是引起当前冠状病毒疾病2019（COVID-19）暴发的β-cov-2。大的- 比例尺诊断测试和大规模筛查是用于遏制暴发的关键工具，尤其是 对于像SARS-COV-2一样可传播的东西很重要。而各种临床标本（例如血液） 咽拭子，唾液，肛门拭子和尿液表明，感染患者存在病毒， 由于唾液的易于收集，最近引起了人们对唾液样品的使用 收集潜力和适应性。尽管有这些优势，但检测SARS-COV-2 RNA，抗原或 唾液样品中的病毒是可变的，范围从30％到100％敏感性，因为唾液是一个复杂的事实 生物分解。这种高变异性还意味着几乎所有的背景信号往往会有高度的信号 测试的分子测定法，该测定方法掩盖了准确的测试和快速跟踪功能。为了满足这种需求， CERES纳米科学提议对现有阶段I SBIR Grant进行一项有竞争力的1年补充 （1R43GM135943; 02/01/2020-10/31/2020; NIGMS）测试使用其专有和专利的可行性 Nanotrap®技术可显着改善使用现有的SARS-COV-2从唾液样品中检测 当今市场上的分子诊断测定法。这种补充目标属于正在进行的范围 资助的项目，正在评估使用纳米颗粒颗粒改善共同提取的可行性 污染物（包括病毒）从牛血清。补充工作将应用类似的工作流程 评估利用纳米颗粒颗粒和工作流程的可行性 以及大量的唾液和生物群体的全血和血清标本，用于存在sars-cov- 2病毒或抗体。